Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Protagonist Therapeutics Inc's Business Segments
Protagonist Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 56
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 56 | 100% |
Description of Protagonist Therapeutics Inc
Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of innovative peptide-based drugs to address unmet medical needs. The company was founded in 2001 and is headquartered in Newark, California, United States.
Protagonist Therapeutics is dedicated to leveraging the power of peptides, which are short chains of amino acids that play crucial roles in various biological processes, to develop therapeutic solutions for diseases that currently have limited treatment options. By targeting specific disease targets using peptide-based drugs, the company aims to provide patients with safer and more effective treatment options compared to traditional small molecules or biologics.
Peptides have numerous advantages as therapeutic agents, including high specificity, low immunogenicity, and excellent safety profiles. Protagonist Therapeutics utilizes its proprietary technology platform, called Peptidomics, to design and optimize peptide-based therapeutics with desired properties such as stability, selectivity, and oral bioavailability.
The company's pipeline includes a diverse range of programs in different stages of development, targeting various disease indications. Protagonist Therapeutics' lead product candidate is PTG-300, which is being developed for the treatment of iron overload disorders such as hereditary hemochromatosis and beta-thalassemia. PTG-300 is a hepcidin mimetic peptide designed to regulate iron homeostasis by inhibiting iron absorption and mobilizing excess iron from tissues.
Another important program in the company's pipeline is PTG-200, being developed for the treatment of inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. PTG-200 is an oral interleukin-23 receptor antagonist designed to modulate the activity of the immune system and reduce the inflammation associated with IBD.
Protagonist Therapeutics has also partnered with major pharmaceutical companies like Janssen Biotech, a subsidiary of Johnson & Johnson, to develop and commercialize certain peptide-based drug candidates. These collaborations help the company in bringing its innovative therapies to market while leveraging the resources and expertise of its partners.
In addition to its research and development efforts, Protagonist Therapeutics also focuses on advancing its manufacturing capabilities to support the eventual commercialization of its pipeline products. The company strives to ensure the scalability and consistency of its manufacturing processes to meet the demand once regulatory approvals are obtained.
Overall, Protagonist Therapeutics Inc. is a biopharmaceutical company that harnesses the therapeutic potential of peptides to develop innovative drugs for various disease indications. With its dedication to scientific innovation, a strong pipeline of product candidates, and strategic partnerships, the company aims to make a significant impact on patients' lives and the field of medicine.
Protagonist Therapeutics is dedicated to leveraging the power of peptides, which are short chains of amino acids that play crucial roles in various biological processes, to develop therapeutic solutions for diseases that currently have limited treatment options. By targeting specific disease targets using peptide-based drugs, the company aims to provide patients with safer and more effective treatment options compared to traditional small molecules or biologics.
Peptides have numerous advantages as therapeutic agents, including high specificity, low immunogenicity, and excellent safety profiles. Protagonist Therapeutics utilizes its proprietary technology platform, called Peptidomics, to design and optimize peptide-based therapeutics with desired properties such as stability, selectivity, and oral bioavailability.
The company's pipeline includes a diverse range of programs in different stages of development, targeting various disease indications. Protagonist Therapeutics' lead product candidate is PTG-300, which is being developed for the treatment of iron overload disorders such as hereditary hemochromatosis and beta-thalassemia. PTG-300 is a hepcidin mimetic peptide designed to regulate iron homeostasis by inhibiting iron absorption and mobilizing excess iron from tissues.
Another important program in the company's pipeline is PTG-200, being developed for the treatment of inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. PTG-200 is an oral interleukin-23 receptor antagonist designed to modulate the activity of the immune system and reduce the inflammation associated with IBD.
Protagonist Therapeutics has also partnered with major pharmaceutical companies like Janssen Biotech, a subsidiary of Johnson & Johnson, to develop and commercialize certain peptide-based drug candidates. These collaborations help the company in bringing its innovative therapies to market while leveraging the resources and expertise of its partners.
In addition to its research and development efforts, Protagonist Therapeutics also focuses on advancing its manufacturing capabilities to support the eventual commercialization of its pipeline products. The company strives to ensure the scalability and consistency of its manufacturing processes to meet the demand once regulatory approvals are obtained.
Overall, Protagonist Therapeutics Inc. is a biopharmaceutical company that harnesses the therapeutic potential of peptides to develop innovative drugs for various disease indications. With its dedication to scientific innovation, a strong pipeline of product candidates, and strategic partnerships, the company aims to make a significant impact on patients' lives and the field of medicine.
Protagonist Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions, particularly in the areas of gastrointestinal diseases and inflammation. The companys primary segments include research and development (R&D), clinical development, and commercial operations. Below is a detailed exploration of the segments, products, and services offered by Protagonist Therapeutics.
1. Research and Development (R&D):
Protagonist Therapeutics places a significant emphasis on R&D to drive innovation in peptide-based therapeutics. Their research leverages proprietary peptide technology platforms to discover and develop novel treatments.
Key Areas of Focus:
- Gastrointestinal (GI) Disorders: The company is dedicated to developing therapies for diseases like inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohns disease.
- Autoimmune Disorders: The firms R&D also targets other inflammatory and autoimmune conditions where peptide therapeutics can be beneficial.
Clinical Development:
Protagonist follows a systematic approach to clinical trial design and execution to ensure robust data generation for their products.
Pipeline Products:
Protagonist has a diverse pipeline of drug candidates in various stages of clinical development:
- PTG-100: One of the most advanced drug candidates, PTG-100 is an oral peptide therapeutic designed to treat ulcerative colitis. Clinical trials have focused on assessing its safety and efficacy in patients.
- PTG-200: This product is another oral peptide therapy aimed at treating moderate to severe ulcerative colitis and Crohns disease. Protagonist has conducted several phases of clinical trials to evaluate its performance.
- PTG-300: This investigational therapy is developed for anemia associated with chronic diseases, focusing on the modulation of hepcidin to improve iron homeostasis.
Clinical Trials:
Protagonist conducts multi-center clinical trials that engage a variety of patient demographics to ensure diverse data collection. The trials are divided into phases:
- Phase 1: Focus on safety and tolerability in healthy volunteers.
- Phase 2: Assess efficacy and optimal dosing in target patient populations.
- Phase 3: Larger scale trials that provide comprehensive data required for regulatory submissions.
Commercial Operations:
While Protagonist is primarily in the R&D and clinical stages for its pipeline products, it prepares for eventual commercialization of successful candidates through strategic partnerships and market access strategies.
Strategic Partnerships:
To enhance their commercialization strategy, Protagonist often collaborates with larger pharmaceutical companies and research institutions. These partnerships can be pivotal in gaining access to broader resources for manufacturing and marketing.
Services:
Alongside its products, Protagonist Therapeutics may often engage in services that support its clinical and operational ventures:
Regulatory Affairs:
Protagonist works closely with regulatory bodies such as the FDA to navigate the complexities of drug approval processes. This includes preparing submissions for Investigational New Drug (IND) applications and New Drug Applications (NDA).
Clinical Supply Manufacturing:
The company may provide support in the manufacturing of clinical supplies necessary for their trials, ensuring that high-quality therapeutic compounds are available for research.
Patient Engagement:
Protagonist recognizes the importance of engaging with patient communities to understand their needs and incorporate their feedback into product development and trial design.
Summary:
Protagonist Therapeutics Inc. stands at the forefront of biopharmaceutical innovation with a focus on peptide-based therapies targeting gastrointestinal and autoimmune disorders. Their structured approach, from R&D through to clinical trials and commercial preparations, illustrates a commitment to addressing unmet medical needs. The companys evolving product pipeline reflects its dedication to developing effective therapies that have the potential to transform patient care.
1. Research and Development (R&D):
Protagonist Therapeutics places a significant emphasis on R&D to drive innovation in peptide-based therapeutics. Their research leverages proprietary peptide technology platforms to discover and develop novel treatments.
Key Areas of Focus:
- Gastrointestinal (GI) Disorders: The company is dedicated to developing therapies for diseases like inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohns disease.
- Autoimmune Disorders: The firms R&D also targets other inflammatory and autoimmune conditions where peptide therapeutics can be beneficial.
Clinical Development:
Protagonist follows a systematic approach to clinical trial design and execution to ensure robust data generation for their products.
Pipeline Products:
Protagonist has a diverse pipeline of drug candidates in various stages of clinical development:
- PTG-100: One of the most advanced drug candidates, PTG-100 is an oral peptide therapeutic designed to treat ulcerative colitis. Clinical trials have focused on assessing its safety and efficacy in patients.
- PTG-200: This product is another oral peptide therapy aimed at treating moderate to severe ulcerative colitis and Crohns disease. Protagonist has conducted several phases of clinical trials to evaluate its performance.
- PTG-300: This investigational therapy is developed for anemia associated with chronic diseases, focusing on the modulation of hepcidin to improve iron homeostasis.
Clinical Trials:
Protagonist conducts multi-center clinical trials that engage a variety of patient demographics to ensure diverse data collection. The trials are divided into phases:
- Phase 1: Focus on safety and tolerability in healthy volunteers.
- Phase 2: Assess efficacy and optimal dosing in target patient populations.
- Phase 3: Larger scale trials that provide comprehensive data required for regulatory submissions.
Commercial Operations:
While Protagonist is primarily in the R&D and clinical stages for its pipeline products, it prepares for eventual commercialization of successful candidates through strategic partnerships and market access strategies.
Strategic Partnerships:
To enhance their commercialization strategy, Protagonist often collaborates with larger pharmaceutical companies and research institutions. These partnerships can be pivotal in gaining access to broader resources for manufacturing and marketing.
Services:
Alongside its products, Protagonist Therapeutics may often engage in services that support its clinical and operational ventures:
Regulatory Affairs:
Protagonist works closely with regulatory bodies such as the FDA to navigate the complexities of drug approval processes. This includes preparing submissions for Investigational New Drug (IND) applications and New Drug Applications (NDA).
Clinical Supply Manufacturing:
The company may provide support in the manufacturing of clinical supplies necessary for their trials, ensuring that high-quality therapeutic compounds are available for research.
Patient Engagement:
Protagonist recognizes the importance of engaging with patient communities to understand their needs and incorporate their feedback into product development and trial design.
Summary:
Protagonist Therapeutics Inc. stands at the forefront of biopharmaceutical innovation with a focus on peptide-based therapies targeting gastrointestinal and autoimmune disorders. Their structured approach, from R&D through to clinical trials and commercial preparations, illustrates a commitment to addressing unmet medical needs. The companys evolving product pipeline reflects its dedication to developing effective therapies that have the potential to transform patient care.